Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression

American Journal of Clinical Nutrition

Volumn 110, Issue 1, 2019, Pages 139-149

  Sharpton, Suzanne R ^a   Maraj, Bharat ^a   Harding Theobald, Emily ^a   Vittinghoff, Eric ^b   Terrault, Norah A ^c  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fecal microbiota transplantation; Microbiome; Nonalcoholic fatty liver; Probiotics; Synbiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; PLACEBO; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT; TRIACYLGLYCEROL;

BODY MASS; CLINICAL OUTCOME; DATA BASE; ELASTOGRAPHY; FATTY LIVER; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; META ANALYSIS; MICROBIOME; NONALCOHOLIC FATTY LIVER; PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEWS AND META-ANALYSES; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ULTRASOUND; ADULT; BLOOD; CHILD; DRUG EFFECT; INTESTINE FLORA; LIVER; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; CHILD; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; INSULIN RESISTANCE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNBIOTICS; TRIGLYCERIDES;

EID: 85068617998     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.1093/ajcn/nqz042     Document Type: Review

References (50)

1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-33.
2. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-72.
3. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, et al. Current and future therapeutic regimens for non-Alcoholic fatty liver disease (NAFLD) and non-Alcoholic steatohepatitis (NASH). Hepatology 2018;68(1):361-71.
4. Marek RJ, Coulon SM, Brown LD, Lydecker JA, Marek S, Malcolm R, O'Neil PM. Characteristics of weight loss trajectories in a comprehensive lifestyle intervention. Obesity 2017;25(12):2062-7.
5. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146:1513-24.
6. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016;13:412-25.
7. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-50.
8. Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012;7:e45425.
9. Okubo H, Sakoda H,KushiyamaA, Fujishiro M, NakatsuY, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, et al. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model.AmJ Physiol Gastrointest Liver Physiol 2013;305:G911-8.
10. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, et al. Intestinal microbiota determines development of non-Alcoholic fatty liver disease in mice. Gut 2013;62:1787-94.
11. Turnbaugh PJ, Ley RE,Mahowald MA,Magrini V, Mardis ER, Gordon JI. An obesity-Associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
12. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369-79.
13. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on FMT 2015: Indications, methodologies, mechanisms and outlook. Gastroenterology 2015;149:223-37.
14. Lirussi F, Orando S, Orlando R. Probiotics for non-Alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007 Jan 24;(1):CD005165.
15. S Lavekar A, V Raje D, Manohar T, A Lavekar A. Role of probiotics in the treatment of nonalcoholic fatty liver disease: A meta-Analysis. Euroasian J Hepatogastroenterol 2017;7:130-7.
16. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-Analysis.World J Gastroenterol 2013;19:6911-8.
17. Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: A meta-Analysis of randomized controlled trials. Hepatol Res 2016;46:1226-33.
18. Loman BR, Hernandez-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: A systematic review and meta-Analysis. Nutr Rev 2018;76(11):822-39.
19. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012;36(1):13-20.
20. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
21. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther 2014;39:1276-85.
22. Aller R, Luis D, Izaola O, Conde R, Gonzalez SagradoM, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011;15:1090-5.
23. Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-Alcoholic fatty liver disease: A randomized clinical trial. Middle East J Dig Dis 2017;9:150-7.
24. Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr 2017;64:413-7.
25. Kobyliak N, Abenavoli L, Mykhalchyshyn G, Kononenko L, Boccuto L, Kyriienko D, Dynnyk O. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: Evidence from a randomized clinical trial. J Gastrointestin Liver Dis 2018;27:41-49.
26. Monem SM. Probiotic therapy in patients with nonalcoholic steatohepatitis in Zagazig University Hospitals. Euroasian J Hepatogastroenterol 2017;7:101-6.
27. Nabavi S, RafrafM, SomiMH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 2014;97:7386-93.
28. Sepideh A, Karim P, Hossein A, Leila R, Hamdollah M, Mohammad EG, Mojtaba S, Mohammad S, Ghader G, Seyed Moayed A. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial. J Am Coll Nutr 2016;35: 500-5.
29. Vajro P, Mandato C, Licenziati ME, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52:740-3.
30. Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-Alcoholic fatty liver disease: A clinical trial. Int J Prev Med 2016;7:59.
31. Ekhlasi G, Mohammadi RK, Agah S, Zarrati M, Hosseini AF, Arabshahi SS, Shidfar F. Do symbiotic and vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci 2016;21: 106.
32. Ferolla SM, Couto CA, Costa Silva L, Armiliato GNA, Pereira CAS, Martins FS, Ferrari MdLA, Vilela EG, Torres HOG, Cunha AS, et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with non-Alcoholic steatohepatitis. Nutrients 2016;8(7): 397.
33. Javadi L, GhavamiM, Khoshbaten M, Safaiyan A, Barzegari A, Gargari BP. The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial. Iranian Red Crescent Medical Journal 2017;19(4): E46017.
34. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012;57: 545-53.
35. Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-Alcoholic steatohepatitis: A pilot trial. J Dig Dis 2017;18:698-703.
36. Shavakhi A, Minakari M, Firouzian H, Assali R, Hekmatdoost A, Ferns G. Effect of a probiotic and metformin on liver aminotransferases in non-Alcoholic steatohepatitis: A double blind randomized clinical trial. Int J Prev Med 2013;4:531-7.
37. Wong VWS, Wong GLH, Chim AML, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013;12:256-62.
38. Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-Alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr 2017;117:662-8.
39. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014;99:535-42.
40. Sayari S, Neishaboori H, JameshoraniM. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepatol 2018;24(3):331-8.
41. Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Nutr 2018;148(8): 1276-84.
42. Del Chierico F, Nobili V, Vernocchi P, Russo A, Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology 2017;65(2):451-64.
43. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9.
44. Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV. Altered gut microbial energy and metabolism in children with nonalcoholic fatty liver disease. FEMS Microbiol Ecol 2015;91:1-9.
45. Quigley E. Prebiotics and probiotics in digestive health. Clin Gastroenterol Hepatol 2019;17(2):333-44.
46. Sharpton SR, Ajmera V, Loomba R. Emerging role of gut microbiome in nonalcoholic fatty liver disease: From composition to function. Clin Gastroenterol Hepatol 2019;17(2):296-306.
47. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-6.e7.
48. Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metabolism 2017;26:611-619.e6.
49. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, et al. Diagnostic modalities for non-Alcoholic fatty liver disease (NAFLD), non-Alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology 2018;68(1):349-60.
50. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis 2015;60 Suppl 2:S129-34.